12 Years of Transformative Growth in Pharmaceuticals Sector Driving Affordable Healthcare and Atmanirbhar Bharat

1. At a Glance

• India's pharma sector has been positioned as the "Pharmacy of the World" — 3rd largest by volume, supplying ~20% of global generics and 60% of global vaccines [2].
• The Department of Pharmaceuticals (DoP), Ministry of Chemicals & Fertilisers runs the architecture of PMBJP (Jan Aushadhi), PLI (Pharma + Bulk Drug + Medical Devices), Bulk Drug Parks & Medical Device Parks [1][3].
• Aspirants must memorise the dual track: affordable access (PMBJP) + Atmanirbharta in APIs/medical devices (PLI/Parks).

2. Why in the News

• 17 June 2026 PIB release marked 12 years of transformative growth of the pharma sector — flagship metrics: Jan Aushadhi Kendras (JAKs) up from 84 (2014) to 19,200+ (2026); PLI Pharma cumulative investment ₹42,694 cr, 1.13 lakh+ jobs; Medical Devices PLI sales ₹29,400 cr [1].

3. Background & Evolution

• PMBJP launched in 2008 as Jan Aushadhi Scheme; revamped & rebranded as Pradhan Mantri Bhartiya Janaushadhi Pariyojana in 2015 under BPPI (Bureau of Pharma & Medical Devices PSUs of India) [5].
• PLI 1.0 for Bulk Drugs (KSMs/DIs/APIs): notified 2020, outlay ₹6,940 cr to cut import dependence (esp. from China) [3].
• PLI 2.0 for Pharmaceuticals: notified 2021, outlay ₹15,000 cr, three product categories [1].
• Bulk Drug Parks Scheme: 2020; three parks sanctioned in Andhra Pradesh, Gujarat, Himachal Pradesh, central assistance ₹1,000 cr each [3].
• PLI for Medical Devices: 2020, outlay ₹3,420 cr [1].

4. Core Static Facts

• Implementing Ministry: Ministry of Chemicals & Fertilisers → Department of Pharmaceuticals [1].
• PMBJP Implementing Agency: PMBI (Pharmaceuticals & Medical Devices Bureau of India), formerly BPPI [5].
• JAKs (2026): 19,200+ nationwide; North East: 1 → 417 in 12 years [1].
• PMBJP product basket: ~2,110 medicines + 315 medical devices, 29 therapeutic groups [2].
• Citizen savings via PMBJP: ₹40,000 cr+ in healthcare expenditure [4].
• PLI Pharma: cumulative investment ₹42,694.89 cr, cumulative sales ₹3,43,215.27 cr, employment 1.13 lakh+ [4].
• PLI Bulk Drugs: committed investment ₹3,938.5 cr exceeded — actual ₹4,570 cr by 3rd year (March 2025) [3].
• PLI Medical Devices: cumulative sales ₹29,400 cr [1].
• Indian pharma exports: India is 3rd largest by volume, 14th by value; supplies generics to 200+ countries [2].

5. Multi-Dimensional Analysis

Economic

• PLI schemes anchor import substitution for APIs/KSMs, cutting dependence on China (~70% pre-2020 API import share) [3].
• Pharma PLI cumulative sales (~₹3.43 lakh cr) signal scale-up of high-value formulations and biologics [4].

Social

• PMBJP delivers generics at 50–90% discount vs branded equivalents, advancing Right to Health (Art 21 — judicial expansion) [5].
• North-East penetration (1→417 JAKs) addresses regional health-access inequity [1].

Strategic / Atmanirbhar

• Bulk Drug Parks + API PLI reduce strategic vulnerability exposed during COVID-19 supply shocks [3].
• Reinforces "Pharmacy of the World" branding in vaccine diplomacy (Vaccine Maitri) [2].

Scientific / Technological

• PRIP scheme (Promotion of Research & Innovation in Pharma MedTech), outlay ₹5,000 cr, targets innovation in complex generics, biosimilars, phytopharmaceuticals [2].

Administrative

• Multi-arm delivery: CDSCO regulates drugs; NPPA controls prices via DPCO 2013; DoP runs schemes — overlapping mandates a known bottleneck.

6. Recent Developments (last 12-18 months)

• 17 June 2026: PIB "12 Years" review released — flagship numbers above [1].
• March 2026: JAKs operational figure 18,646 (as of 28.02.2026); product basket expanded to 2,110 medicines [2].
• March 2025: PLI Bulk Drugs investment crossed committed targets (₹4,570 cr) [3].
• Continuous addition of new Jan Aushadhi products incl. Suvidha sanitary napkin at ₹1 [5].

7. Prelims Hooks

• PMBJP is implemented by PMBI (renamed from BPPI), under DoP [5].
• PMBJP relaunched/rebranded in 2015 (original Jan Aushadhi: 2008) [5].
• Three Bulk Drug Parks: Andhra Pradesh, Gujarat, Himachal Pradesh — central assistance ₹1,000 cr each [3].
• PLI Pharma outlay: ₹15,000 cr (2021) [1].
• PLI Bulk Drugs outlay: ₹6,940 cr (2020) [3].
• PLI Medical Devices outlay: ₹3,420 cr [1].
• PRIP scheme outlay: ₹5,000 cr for R&D in pharma-MedTech [2].
• India supplies ~20% of global generics by volume and 60% of global vaccines [2].
• JAKs grew from 84 (2014) → 19,200+ (2026) [1].
• Cumulative citizen savings via PMBJP: ₹40,000 cr+ [4].
• PLI Pharma employment generated: 1.13 lakh+ [1].
• North-East JAKs: 1 → 417 in 12 years [1].
• Parent Ministry: Chemicals & Fertilisers (NOT Health & Family Welfare) [1].

8. Mains Relevance

• GS-II: Government policies & interventions for development in health sector; Issues relating to development & management of Social Sector/Services — Health.
• GS-III: Indian Economy — growth, development; Effects of liberalization; Science & Technology — indigenization; Atmanirbhar Bharat.
• Plausible stems: 1. "Critically examine how PMBJP and PLI schemes together advance both affordable healthcare and Atmanirbharta in India's pharma sector." (GS-II/III, 15 marks) 2. "Discuss the strategic importance of indigenising bulk drug (API) manufacturing. What are the bottlenecks?" (GS-III, 10 marks) 3. "India is the 'Pharmacy of the World' yet struggles with API import dependence. Examine." (GS-III, 15 marks)

9. Related Topics to Study Next

• NPPA & DPCO 2013 — price-control architecture for essential medicines.
• CDSCO & Drugs and Cosmetics Act, 1940 — regulatory backbone.
• Ayushman Bharat (PM-JAY, ABHA, HWCs) — demand-side health financing.
• Vaccine Maitri & COVAX — pharma diplomacy.
• TRIPS & Compulsory Licensing (Sec 84, Patents Act 1970) — generics IPR architecture.
• National Medical Devices Policy 2023 — sectoral linkage.
• PRIP Scheme — innovation ecosystem.
• National List of Essential Medicines (NLEM 2022) — price-cap basis.

10. Common Errors / Trap Areas

• PMBJP nodal ministry is Chemicals & Fertilisers, NOT Health & Family Welfare.
• Implementing agency is PMBI (renamed), not BPPI — both names appear in older sources.
• Bulk Drug Parks are only three (AP/Gujarat/HP) — not in Telangana/MP.
• PLI Pharma (₹15,000 cr) vs PLI Bulk Drugs (₹6,940 cr) vs PLI Medical Devices (₹3,420 cr) — three distinct schemes, often confused.
• Original Jan Aushadhi was 2008 (UPA era); rebrand to PMBJP was 2015 — both years are testable.